RE: Admission of shares.16 Oct 2024 10:12
Father Ted, toxicology studies have been conducted, it seems from time immemorial;
From March 2022
"Dr John Reader, Chief Scientific Officer of Sareum, commented: "We are pleased to have successfully completed the preclinical toxicology studies and have now received the final report, which will form a key part of the planned CTA application for SDC-1801. We are particularly encouraged that the promising data and progress with the manufacture of SDC-1801 in capsule form continue to support our intention to file the CTA application in mid-year and our plan to begin the first clinical trial with SDC-1801 during H2 2022."
They need to come up with something, otherwise all the current goings on are just to buy time.